Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Secondary Progressive Multiple Sclerosis Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Secondary Progressive Multiple Sclerosis Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Secondary Progressive Multiple Sclerosis Drug Supply by Company

    • 2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Company
    • 2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Company
    • 2.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Company
    • 2.4 Secondary Progressive Multiple Sclerosis Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Secondary Progressive Multiple Sclerosis Drug Market Status by Category

    • 3.1 Secondary Progressive Multiple Sclerosis Drug Category Introduction
      • 3.1.1 Inebilizumab
      • 3.1.2 GLX-1112
      • 3.1.3 DC-TAB
      • 3.1.4 Etomoxir
      • 3.1.5 IB-MS
      • 3.1.6 Others
    • 3.2 Global Secondary Progressive Multiple Sclerosis Drug Market by Category
      • 3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Secondary Progressive Multiple Sclerosis Drug Market Status by End User/Segment

    • 4.1 Secondary Progressive Multiple Sclerosis Drug Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Secondary Progressive Multiple Sclerosis Drug Market by End User/Segment
      • 4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Secondary Progressive Multiple Sclerosis Drug Market Status by Region

    • 5.1 Global Secondary Progressive Multiple Sclerosis Drug Market by Region
      • 5.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Region
      • 5.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region
    • 5.2 North America Secondary Progressive Multiple Sclerosis Drug Market Status
    • 5.3 Europe Secondary Progressive Multiple Sclerosis Drug Market Status
    • 5.4 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Status
    • 5.5 Central & South America Secondary Progressive Multiple Sclerosis Drug Market Status
    • 5.6 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Market Status

    6 North America Secondary Progressive Multiple Sclerosis Drug Market Status

    • 6.1 North America Secondary Progressive Multiple Sclerosis Drug Market by Country
      • 6.1.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Secondary Progressive Multiple Sclerosis Drug Market Status

    • 7.1 Europe Secondary Progressive Multiple Sclerosis Drug Market by Country
      • 7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Status

    • 8.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market by Country
      • 8.1.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Secondary Progressive Multiple Sclerosis Drug Market Status

    • 9.1 Central & South America Secondary Progressive Multiple Sclerosis Drug Market by Country
      • 9.1.1 Central & South America Secondary Progressive Multiple Sclerosis Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Market Status

    • 10.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Market by Country
      • 10.1.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Secondary Progressive Multiple Sclerosis Drug Manufacturing Cost Analysis
    • 11.5 Secondary Progressive Multiple Sclerosis Drug Sales Channel and Distributors Analysis
      • 11.5.1 Secondary Progressive Multiple Sclerosis Drug Sales Channel
      • 11.5.2 Secondary Progressive Multiple Sclerosis Drug Distributors
    • 11.6 Secondary Progressive Multiple Sclerosis Drug Downstream Major Buyers

    12 Global Secondary Progressive Multiple Sclerosis Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Category
      • 12.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Forecast by Category
      • 12.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value Forecast by Category
      • 12.2.3 Global Secondary Progressive Multiple Sclerosis Drug Price Forecast by Category
    • 12.3 Global Secondary Progressive Multiple Sclerosis Drug Forecast by End User/Segment
      • 12.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Secondary Progressive Multiple Sclerosis Drug Price Forecast by End User/Segment

    13 Global Secondary Progressive Multiple Sclerosis Drug Market Forecast by Region/Country

    • 13.1 Global Secondary Progressive Multiple Sclerosis Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Xenetic Biosciences (UK) Limited
      • 14.1.1 Company Information
      • 14.1.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.1.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Opexa Therapeutics, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.2.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Novartis AG
      • 14.3.1 Company Information
      • 14.3.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.3.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Meta-IQ ApS
      • 14.4.1 Company Information
      • 14.4.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.4.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Merck KGaA
      • 14.5.1 Company Information
      • 14.5.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.5.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 MedImmune, LLC
      • 14.6.1 Company Information
      • 14.6.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.6.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 MedDay SA
      • 14.7.1 Company Information
      • 14.7.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.7.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Mallinckrodt Plc
      • 14.8.1 Company Information
      • 14.8.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.8.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Kyorin Pharmaceutical Co., Ltd.
      • 14.9.1 Company Information
      • 14.9.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Innate Immunotherapeutics Ltd
      • 14.10.1 Company Information
      • 14.10.2 Secondary Progressive Multiple Sclerosis Drug Product Introduction
      • 14.10.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Immune Response BioPharma, Inc.
    • 14.12 Glialogix, Inc.
    • 14.13 Genzyme Corporation
    • 14.14 F. Hoffmann-La Roche Ltd.
    • 14.15 Biogen, Inc.
    • 14.16 Actelion Ltd
    • 14.17 AB Science SA

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Secondary Progressive Multiple Sclerosis Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Secondary Progressive Multiple Sclerosis Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Inebilizumab
      GLX-1112
      DC-TAB
      Etomoxir
      IB-MS
      Others

      Segmented by End User/Segment
      Hospital
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Xenetic Biosciences (UK) Limited
      Opexa Therapeutics, Inc.
      Novartis AG
      Meta-IQ ApS
      Merck KGaA
      MedImmune, LLC
      MedDay SA
      Mallinckrodt Plc
      Kyorin Pharmaceutical Co., Ltd.
      Innate Immunotherapeutics Ltd
      Immune Response BioPharma, Inc.
      Glialogix, Inc.
      Genzyme Corporation
      F. Hoffmann-La Roche Ltd.
      Biogen, Inc.
      Actelion Ltd
      AB Science SA
      Buy now